AstraZeneca PLC, as Issuer and The Bank of New York Mellon, as Trustee Indenture Dated as of May 28, 2021 ASTRAZENECA PLC Reconciliation and tie between Trust Indenture Act of 1939, as amended including by the Trust Indenture Reform Act of 1990, and...Indenture • May 28th, 2021 • Astrazeneca PLC • Pharmaceutical preparations • New York
THIS INDENTURE, dated as of May 28, 2021, between AstraZeneca PLC, an English public limited company, as issuer (the “Issuer”), and The Bank of New York Mellon, a New York banking corporation, as trustee (the “Trustee”),
ASTRAZENECA PLC ASTRAZENECA FINANCE LLC Debt Securities UNDERWRITING AGREEMENTUnderwriting Agreement • May 28th, 2021 • Astrazeneca PLC • Pharmaceutical preparations • New York
From time to time AstraZeneca PLC, a company organized under the laws of England (the “Company”), and AstraZeneca Finance LLC, a Delaware limited liability company (“AZ Finance” and, together with the Company, the “Issuers” and each individually, an “Issuer”), propose to enter into one or more Pricing Agreements (each a “Pricing Agreement”) substantially in the form of Annex I hereto, with such additions and deletions as the parties thereto may determine, and subject to the terms and conditions stated herein, to issue and sell to the firms named in Schedule I to the applicable Pricing Agreement (such firms constituting the “Underwriters” with respect to such Pricing Agreement and the securities specified therein), certain of their debt securities (the “Notes”), with the Company to guarantee the debt securities to be issued by AZ Finance (such guarantee, the “Guarantee” and together with the Notes, the “Securities”), as specified in Schedule II to such Pricing Agreement (with respect to
Pricing AgreementPricing Agreement • May 28th, 2021 • Astrazeneca PLC • Pharmaceutical preparations
AstraZeneca Finance LLC (the “Issuer”) proposes, subject to the terms and conditions stated herein and in the Underwriting Agreement dated May 25, 2021 (the “Underwriting Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) the Notes specified in Schedule II hereto, guaranteed by AstraZeneca PLC, a company organized under the laws of England (the “Company,” such guarantee, the “Guarantee” and together with the Notes, the “Designated Securities”). Each of the provisions of the Underwriting Agreement is incorporated herein by reference in its entirety, and shall be deemed to be a part of this Agreement to the same extent as if such provisions had been set forth in full herein; and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Pricing Agreement, except that each representation and warranty which refers to the Basic Prospectus, Pricing Disclosure Package or the Prosp
Pricing AgreementPricing Agreement • May 28th, 2021 • Astrazeneca PLC • Pharmaceutical preparations
AstraZeneca PLC (the “Issuer”) proposes, subject to the terms and conditions stated herein and in the Underwriting Agreement dated May 25, 2021 (the “Underwriting Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) the Notes specified in Schedule II hereto (the “Designated Securities”). Each of the provisions of the Underwriting Agreement is incorporated herein by reference in its entirety, and shall be deemed to be a part of this Agreement to the same extent as if such provisions had been set forth in full herein; and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Pricing Agreement, except that each representation and warranty which refers to the Basic Prospectus, Pricing Disclosure Package or the Prospectus in Section 2 of the Underwriting Agreement shall be deemed to be a representation or warranty as of the date of the Underwriting Agreement in relation to th
